Bilal Arif sold $258k of SRPT
Chief Tech Ops Officer at Sarepta Therapeutics, Inc.. 2,000 shares at an average of $128.84, traded Mar 1, 2024, filed Mar 5, 2024.
Score components
- +15RoleOfficer
- +13Trade size$258k at market
- 0Share of holdings soldSold 6.9% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-026606, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2024 | FTax withholding Common Stock | -251 | $126.19 | $32k | 22,836 | Mar 5, 2024 |
| Mar 1, 2024 | AGrant or award Common Stock | +6,000 | $0.00 | $0 | 28,836 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock | -1,543 | $128.58 | $198k | 27,293 | Mar 5, 2024 |
| Mar 1, 2024 | SOpen-market sale Common Stock | -457 | $129.71 | $59k | 26,836 | Mar 5, 2024 |
| Mar 1, 2024 | FTax withholding Common Stock | -114 | $126.19 | $14k | 26,722 | Mar 5, 2024 |
| Mar 1, 2024 | AGrant or award Stock Option (right to buy)derivative | -12,500 | $0.00 | $0 | 12,500 | Mar 5, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Operating Officer | $294k 13,187 shares | -6% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 33Weak | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $6.3M 38,957 shares | -69% | |
| 18Weak | Sarepta Therapeutics, Inc. | Dallan Murray Chief Customer Officer | $509k 3,635 shares | -17% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $94k 761 shares | -9% | |
| 50Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.8M 15,000 shares | -40% | |
| 56Moderate | Sarepta Therapeutics, Inc. | Stephen Mayo director | $385k 3,135 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.